Indications and uses
Helps prevent sunburn.
LBEL REPLENISHING FOUNDATION SPF 14
- Manufacturer
- Ventura Corporation LTD | Bel Star S.A. (Colombia)
- Effective date
- 2013-12-17
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- legacy-cache
- Hydrated at
- 2026-08-02 01:37:51
Label at a glance#
ProductLBEL REPLENISHING FOUNDATION SPF 14 (CLAIRE 1) - BEIGE
Active ingredientOctinoxate
Label structure18 sections
Dosage and administration
Apply liberally and evenly 15 minutes before sun exposure. Reapply at least every 2 hours Use a water resistant sunscreen if swimming or sweating. Children under 6 months of age: Ask a doctor Apply to the forehead, nose, chin and both cheeks. Blend with CIrcular motion and spread softly without stretching the skin.
Storage and handling
Protect the product in this container from excessive heat and direct sun.
Label contents#
Full prescribing information#
SPL UNCLASSIFIED SECTION
Drug Facts
Active Ingredients
Octinoxate (4.5 %)
Purpose
Sunscreen
Uses
- Helps prevent sunburn.
Warnings
SPL UNCLASSIFIED SECTION
- Skin Cancer / Skin Aging Alert: Spending time in the sun increases your risk of skin cancer and early skin aging. This product has been shown only to help prevent sunburn, not skin cancer or early skin aging.
- For external use only.
OTC - DO NOT USE SECTION
- Do not use on damaged or broken skin.
OTC - WHEN USING SECTION
- When using this product keep out of eyes. Rinse with water to remove.
OTC - STOP USE SECTION
- Stop use and ask a doctor if rash occurs.
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
- Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.
Directions
- Apply liberally and evenly 15 minutes before sun exposure.
- Reapply at least every 2 hours
- Use a water resistant sunscreen if swimming or sweating.
- Children under 6 months of age: Ask a doctor
- Apply to the forehead, nose, chin and both cheeks.
Blend with CIrcular motion and spread softly without stretching the skin.
Other information
- Protect the product in this container from excessive heat and direct sun.
Inactive ingredients
Water, cyclopentasiloxane, butylene glycol, cyclohexasiloxane, phenyl trimethicone, cetyl peg/ppg-10/1 dimethicone, polyglyceryl-4 isostearate, nylon-12 fluorescent brightener 230 salt, hexyl laurate, mannitol, glycerin, ethylene/acrylic acid copolymer, glycine soja (soybean) protein, peg/ppg-18/18 dimethicone, disteardimonium hectorite, sodium chloride, dimethicone, propylene glycol, dimethicone crosspolymer, dimethicone/vinyl dimethicone crosspolymer, diazolidinyl urea, hydrolyzed keratin, dimethiconol, sucrose, methylparaben, serine, fragrance, arginine, cyclodextrin, polyvinylalcohol crosspolymer, pca, bht, macrocystis pyrifera extract, yeast extract, alanine, propylparaben, hydrolyzed wheat protein, carbomer, pvp, threonine, polysorbate 20, disodium succinate, mourera fluviatilis extract, palmitoyl pentapeptide-4.
May contain: titanium dioxide, iron oxides, iron oxides, iron oxides,methicone.
SPL UNCLASSIFIED SECTION
PR: Distributed by Ventura Corporation, Ltd. San Juan, Puerto Rico 00926.
PRINCIPAL DISPLAY PANEL - 30 g Bottle Box - Claire 1 - BEIGE
L'BEL
replenishing foundation SPF 14
Net Weight 1 oz. (30 g)
PRINCIPAL DISPLAY PANEL - 30 g Bottle Box - Claire 2 - BEIGE
L'BEL
replenishing foundation SPF 14
Net Weight 1 oz. (30 g)
PRINCIPAL DISPLAY PANEL - 30 g Bottle Box - Claire 3 - BEIGE
L'BEL
replenishing foundation SPF 14
Net Weight 1 oz. (30 g)
PRINCIPAL DISPLAY PANEL - 30 g Bottle Box - Claire 4 - BEIGE
L'BEL
replenishing foundation SPF 14
Net Weight 1 oz. (30 g)
PRINCIPAL DISPLAY PANEL - 30 g Bottle Box - Medium 5 - BROWN
L'BEL
replenishing foundation SPF 14
Net Weight 1 oz. (30 g)
PRINCIPAL DISPLAY PANEL - 30 g Bottle Box - Medium 6 - BROWN
L'BEL
replenishing foundation SPF 14
Net Weight 1 oz. (30 g)
PRINCIPAL DISPLAY PANEL - 30 g Bottle Box - Medium 7 - BROWN
L'BEL
replenishing foundation SPF 14
Net Weight 1 oz. (30 g)
PRINCIPAL DISPLAY PANEL - 30 g Bottle Box - Obscure 8 - BROWN
L'BEL
replenishing foundation SPF 14
Net Weight 1 oz. (30 g)
PRINCIPAL DISPLAY PANEL - 30 g Bottle Box - Obscure 9 - BROWN
L'BEL
replenishing foundation SPF 14
Net Weight 1 oz. (30 g)
FDA-Initiated Inactive NDC Indexing#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Octinoxate | ACTIVE INGREDIENT | 4Y5P7MUD51 | 1 | |
| Octinoxate | ACTIVE MOIETY | 4Y5P7MUD51 | 1 | |
| ALANINE | INACTIVE INGREDIENT | OF5P57N2ZX | 1 | |
| ARGININE | INACTIVE INGREDIENT | 94ZLA3W45F | 1 | |
| BUTYLATED HYDROXYTOLUENE | INACTIVE INGREDIENT | 1P9D0Z171K | 1 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 1 | |
| CYCLOMETHICONE 5 | INACTIVE INGREDIENT | 0THT5PCI0R | 1 | |
| CYCLOMETHICONE 6 | INACTIVE INGREDIENT | XHK3U310BA | 1 | |
| DIAZOLIDINYL UREA | INACTIVE INGREDIENT | H5RIZ3MPW4 | 1 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 1 | |
| DISTEARDIMONIUM HECTORITE | INACTIVE INGREDIENT | X687XDK09L | 1 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 1 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 1 | |
| HEXYL LAURATE | INACTIVE INGREDIENT | 4CG9F9W01Q | 1 | |
| MACROCYSTIS PYRIFERA | INACTIVE INGREDIENT | K31S3OG5C4 | 1 | |
| MANNITOL | INACTIVE INGREDIENT | 3OWL53L36A | 1 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| PALMITOYL PENTAPEPTIDE-4 | INACTIVE INGREDIENT | KK181SM5JG | 1 | |
| PEG/PPG-18/18 DIMETHICONE | INACTIVE INGREDIENT | 9H0AO7T794 | 1 | |
| PHENYL TRIMETHICONE | INACTIVE INGREDIENT | DR0K5NOJ4R | 1 | |
| PIDOLIC ACID | INACTIVE INGREDIENT | SZB83O1W42 | 1 | |
| POLYGLYCERYL-4 ISOSTEARATE | INACTIVE INGREDIENT | 820DPX33S7 | 1 | |
| POLYSORBATE 20 | INACTIVE INGREDIENT | 7T1F30V5YH | 1 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 1 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 1 | |
| SERINE | INACTIVE INGREDIENT | 452VLY9402 | 1 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 1 | |
| SODIUM SUCCINATE ANHYDROUS | INACTIVE INGREDIENT | V8ZGC8ISR3 | 1 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 1 | |
| THREONINE | INACTIVE INGREDIENT | 2ZD004190S | 1 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 | |
| YEAST | INACTIVE INGREDIENT | 3NY3SM6B8U | 1 |
Products#
Every source-derived product name is available through these pages.
- LBEL REPLENISHING FOUNDATION SPF 14 (CLAIRE 1) - BEIGE
- Octinoxate
- WATER
- CYCLOMETHICONE 5
- BUTYLENE GLYCOL
- CYCLOMETHICONE 6
- PHENYL TRIMETHICONE
- POLYGLYCERYL-4 ISOSTEARATE
- HEXYL LAURATE
- MANNITOL
- GLYCERIN
- PEG/PPG-18/18 DIMETHICONE
- DISTEARDIMONIUM HECTORITE
- SODIUM CHLORIDE
- DIMETHICONE
- PROPYLENE GLYCOL
- DIAZOLIDINYL UREA
- SUCROSE
- METHYLPARABEN
- SERINE
- ARGININE
- PIDOLIC ACID
- BUTYLATED HYDROXYTOLUENE
- MACROCYSTIS PYRIFERA
- YEAST
- ALANINE
- PROPYLPARABEN
- THREONINE
- POLYSORBATE 20
- SODIUM SUCCINATE ANHYDROUS
- PALMITOYL PENTAPEPTIDE-4
- TITANIUM DIOXIDE
- FERRIC OXIDE RED
- LBEL REPLENISHING FOUNDATION SPF 14 (CLAIRE 2) - BEIGE
- LBEL REPLENISHING FOUNDATION SPF 14 (CLAIRE 3) - BEIGE
- LBEL REPLENISHING FOUNDATION SPF 14 (CLAIRE 4) - BEIGE
- LBEL REPLENISHING FOUNDATION SPF 14 (MEDIUM 5) - BROWN
- LBEL REPLENISHING FOUNDATION SPF 14 (MEDIUM 6) - BROWN
- LBEL REPLENISHING FOUNDATION SPF 14 (MEDIUM 7) - BROWN
- LBEL REPLENISHING FOUNDATION SPF 14 (OBSCURE 8) - BROWN
NDC Codes#
Ingredients#
Every source-derived ingredient row is available through these pages.
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUPPOSITORY / VAGINAL | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION, CONCENTRATE / INTRAMUSCULAR | 0.86 %w/v | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | SOLUTION / TOPICAL | 15 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / NASAL | 250 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, ORALLY DISINTEGRATING / SUBLINGUAL | 10.25 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INFILTRATION | 0.35 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION, CONCENTRATE / INTRAVENOUS | 50.33 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / NASAL | 250 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 1568 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRAVASCULAR | 0.86 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUPPOSITORY / VAGINAL | 252 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | NA | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRASYNOVIAL | 4 mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | SUSPENSION / ORAL | 80 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, FILM COATED / ORAL | 100 mg | ||
| ARGININE | ARGININE | 94ZLA3W45F | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | ADJ PH | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / INTRAMUSCULAR | 6 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SPRAY, METERED / NASAL | 36 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CAPSULE / ORAL | 7 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / AURICULAR (OTIC) | 10 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / TOPICAL | 216 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SOLUTION / PARENTERAL | 210 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | CAPSULE, EXTENDED RELEASE / ORAL | 160 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION/ DROPS / OPHTHALMIC | 0.05 %w/w | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET / BUCCAL | 360 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | CREAM / TOPICAL | 0.4 %w/w | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | GEL / TOPICAL | 8 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | CAPSULE, LIQUID FILLED / ORAL | 0.1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / INTRATYMPANIC | 2 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / INTRAOCULAR | 320 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CREAM, AUGMENTED / TOPICAL | 2 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET / BUCCAL | 0.4 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | CREAM / TOPICAL | 6 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET / SUBLINGUAL | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, EMULSION / INTRAVENOUS | 0.62 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SYSTEM / TOPICAL | 21 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SOAP / TOPICAL | 1 %w/w | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 300 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / DENTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SUPPOSITORY, EXTENDED RELEASE / INTRAUTERINE | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / SUBCUTANEOUS | 1486 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | CAPSULE, EXTENDED RELEASE / ORAL | 0.03 mg | ||
| ARGININE | ARGININE | 94ZLA3W45F | POWDER, FOR SOLUTION / INTRAVENOUS | 7.07 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | EMULSION / TOPICAL | 0.2 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / TOPICAL | 210 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, COATED / ORAL | 0.8 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 543 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, DENTIFRICE / DENTAL | 0.03 mg/mg | ||
| TITANIUM DIOXIDE | TITANIUM DIOXIDE | 15FIX9V2JP | SUPPOSITORY / VAGINAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SOLUTION / INTRAVENOUS | 5 mg | ||
| PEG/PPG-18/18 DIMETHICONE | PEG/PPG-18/18 DIMETHICONE | 9H0AO7T794 | GEL / TOPICAL | 1 %w/w | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | 105 mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | NA |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 334e7602-aef1-1b7b-e063-6294a90ad622 | a6a4ec83-ee52-4140-9f2f-8e9e12738ab3 | 2025-04-21 | Warnings | a6a4ec83-ee52-4140-9f2f-8e9e12738ab3 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.